[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 1967

Myocardial Contractile Force in Hemorrhagic Shock: Treatment With Phenoxybenzamine Hydrochloride, Metaproterenol Sulfate, or These Agents Combined

Author Affiliations

Chicago; Urbana, Ill
From the Department of Pharmacology, University of Illinois College of Medicine, Chicago (Drs. Cook and Sherrod), and the Division of Surgery, Carle Clinic and Hospital, Urbana, Ill (Dr. Cooley). Doctor Cook is now at the Gargos Hospital, Balboa Heights, Panama Canal Zone.

Arch Surg. 1967;95(3):500-510. doi:10.1001/archsurg.1967.01330150176022

HEMORRHAGIC shock has been subject of concern to clinicians and has excited considerable interest among scores of investigators. The proper treatment of the patient in hemorrhagic shock constitutes a continuing discussion which has not been fully resolved. For many years, the accepted method of treating the severely hypotensive patient included a vasoconstrictor agent such as levarterenol or metaproteranol sulfate. These agents were effective in producing a marked elevation of blood pressure, but often did not result in the survival of the patient. In the mid-1950's such investigators as Nickerson1 and Lillehei2 suggested that vasodilating agents may offer a more physiologic approach to the treatment of patients in hemorrhagic shock. It was realized that effective tissue perfusion, rather than a normal blood pressure, was a more important factor in the survival of a shocked patient. This current study was conducted to evaluate myocardial performance when induced hemorrhagic shock is